Members of the Executive Board of Merck KGaA

Notes on memberships of statutory supervisory boards and comparable German and foreign supervisory bodies (section 285 sentence 1, No. 10 HGB in conjunction with sections 125 (1) sentence 5 AktG)

XLS

 

 

 

*

Michael Becker was Chief Financial Officer of Merck KGaA until May 31, 2011. After June 1, 2011, Michael Becker remained a General Partner of Merck KGaA, but was no longer a member of the Executive Board of Merck KGaA.

**

Elmar Schnee was a General Partner of Merck KGaA, but was no longer a member of the Executive Board of Merck KGaA in the period from January 1, 2011 to June 30, 2011.

 

Memberships of

Member

(a)
(b)

other statutory supervisory boards and
comparable German and foreign supervisory bodies
of corporations

Karl-Ludwig Kley
Darmstadt
Chairman

(a)


– Bertelsmann AG, Gütersloh
– BMW AG, Munich (Vice Chairman)
– 1. FC Köln GmbH & Co. KGaA, Cologne (Chairman)

Michael Becker*
Darmstadt, Chief Financial Officer (until 5/31/11)

(a)
(b)

– Symrise AG, Holzminden (since May 2011)
– Bâloise Holding AG, Basel, Switzerland

Kai Beckmann
Griesheim, Head of Group Human Resources (since 4/1/11)

no board positions

Stefan Oschmann
Munich, Head of the Pharmaceuticals business sector



(b)

– Merck Serono S.A., (Chairman, since 1/10/11)

Bernd Reckmann
Seeheim-Jugenheim, Head of the Chemicals business sector

(b)
 

– Millipore Corp., Billerica, MA, USA (until 9/28/11)
– Millipore Corp., Cidra, Puerto Rico (until 9/28/11)

Elmar Schnee**
Darmstadt (until 6/30/11)

(b)

– Merck Serono S.A., Coinsins, Switzerland (until 1/10/11)
– ChemGenex Pharmaceuticals Ltd., Geelong, Australia

Matthias Zachert
Bonn, Chief Financial Officer (since 6/1/11)

no board positions

The general partners with no equity interest (Executive Board) manage the business activities in accordance with the laws, the Articles of Association and the rules of procedure. They are appointed by E. Merck KG with the consent of a simple majority of the other general partners. The members of the Executive Board are jointly responsible for the entire management of the company. Certain tasks are assigned to individual Executive Board members based on a responsibility distribution plan. Each Executive Board member promptly informs the other members of any important actions or operations in his respective business area. The Executive Board is responsible for preparing the annual financial statements of Merck KGaA, the quarterly and half-year financial statements, as well as the annual financial statements of the Merck Group. In addition, the Executive Board ensures that all legal provisions, official regulations and the company’s internal policies are abided by, and works to achieve compliance with them by all the companies of the Merck Group. A Group-wide guideline defines in detail which transactions require prior Executive Board approval.

The Executive Board provides the Supervisory Board with regular, up-to-date and comprehensive reports about all company-relevant issues concerning planning, business developments, the risk situation, and risk management. A Supervisory Board resolution regulates further details on the information and reporting duties of the Executive Board vis-à-vis the Supervisory Board.

The Executive Board informs the Board of Partners and the Supervisory Board at least quarterly of the progress of business and the situation of the company. In addition, the Executive Board informs the stated boards at least annually of the company’s annual plans and strategic considerations.

The Executive Board passes its resolutions in meetings that are normally held twice a month.